Chemistry Seminar - 18F-SiFA-Labeled Glycomimetic Dendrimers for Imaging Heparanase in Breast Cancer

Title: 18F-SiFA-Labeled Glycomimetic Dendrimers for Imaging Heparanase in Breast Cancer

Speaker: Dr Justin Bailey, from TRIUMF – Life Sciences Division, Canada

Abstract: This presentation highlights the development of a fluorine-18–labeled radiotracer targeting heparanase, a key enzyme implicated in tumor invasion and metastasis. The tracer is constructed using a SiFA-based isotopic exchange strategy for efficient [¹⁸F]fluoride labeling, coupled with a persulfated glycomimetic dendrimer designed to selectively bind heparanase. Validation in MCF-7 and MDA-MB-231 breast cancer models demonstrated in vitro and in vivo specificity, with uptake and blocking studies confirming target engagement and intriguing pharmacokinetics. The talk will also briefly introduce TRIUMF, Canada’s national particle accelerator centre, and showcase how its infrastructure, isotope production capabilities, and interdisciplinary environment uniquely support translational radiopharmaceutical research—bridging fundamental discovery and applied innovation.

Bio: Dr. Justin Bailey is a radiopharmaceutical scientist at TRIUMF and a former oncology professor at the University of Alberta, where he developed and taught Canada's only undergraduate course featuring hands-on work with open-source radiotracers. His research integrates radiochemistry, molecular imaging, and cancer biology, with a focus on heparanase-targeted PET and therapeutic agents. At TRIUMF, he leads preclinical radiotracer development and works closely with academic and industry collaborators to accelerate the translation of novel isotopes and imaging agents into meaningful health solutions.